Life depends on the precise functioning of several proteins synthesized in cells by ribosomes. This diverse set of proteins, or proteome, is maintained by the robust translation elongation of amino acid sequences in the ribosomes. However, in prokaryotic and eukaryotic cells, this translation-elongation process can be interrupted by intrinsic ribosome destabilization (IRD). A team of researchers from the Tokyo Institute of Technology recently studied IRD in eukaryotic cells using budding yeast and a reconstituted cell-free translation system.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
IRD occurs when positively charged nascent peptides interact with negatively charged ribosomal RNA, leading to the destabilization of ribosomes and the termination of protein synthesis. In their work, published in the journal Nature Communications, the team found that nascent peptides triggered IRD with N-terminals rich in aspartic and glutamic acid sequences, similar to what has been observed in prokaryotic cells.
The researchers also discovered that the accumulation of peptidyl-tRNAs, a byproduct of IRD, inhibited cell growth in yeast lacking peptidyl-tRNA hydrolase, an essential cellular enzyme that recycles peptidyl-tRNAs outside the ribosome complex.
However, the team's bioinformatics analysis revealed a unique mechanism that yeast cells use to reduce the risk of IRD. They found that the proteomes had a biased amino acid distribution, in which the translation elongation process disfavored sequences with aspartic and glutamic acid runs in their N-terminal region. This suggests that the translation defects caused by IRD partly restrict the overall amino acid usage in proteomes.
This study provides new insights into the protein synthesis process in eukaryotic cells and the counteracting mechanisms in place to reduce translation defects. Understanding these factors could potentially improve the expression of recombinant proteins for clinical and industrial applications.